Your fact-checks will appear here
Pharmacovigilance and poison-control reporting have increased due to Ivermectin misuse, with reports of seizures, loss of consciousness, and severe confusion.
Poison control centers and hospitals documented a clear surge in -related exposures and toxicity reports during the era, with public health agencies and academic centers citing increases in calls, eme...
is a well-established antiparasitic with robust evidence and regulatory approval for treating intestinal strongyloidiasis and substantial, though more variable, evidence supporting its use for scabies...
Fixed‑dose ivermectin has been evaluated in a mix of individual‑level meta‑analyses, operational trials, and cohort safety surveillance that together show broadly low rates of common adverse events in...
Reports from poison centers, case series and public-health advisories document that taking formulations or overdosing on can cause gastrointestinal distress, marked neurologic toxicity (confusion, ata...
No published case studies in the supplied reporting document a clear, directly attributed adverse event from coadministration of ivermectin specifically with chemotherapy supportive drugs; small clini...
Clinicians must identify or exclude high Loa loa microfilaremia before giving ivermectin in endemic areas because serious adverse events—including encephalopathy and death—are tightly linked to high c...
High‑dose or prolonged ivermectin use has most often produced mild, transient symptoms—headache, dizziness, nausea, rash and gastrointestinal upset—across clinical studies, but rare serious events inc...
Using veterinary ivermectin preparations or veterinary-level doses in humans carries clear, well-documented risks: veterinary formulations are concentrated for much larger animals and can cause toxic ...